{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.99","value":"-24.0"},{"groupId":"OG001","spread":"30.32","value":"-19.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"description":"Patients rated their pain at baseline and Week 48 using the Visual Analog Scale (VAS) on a scale of 0 (none) to 100 (unbearable pain). A negative change from baseline indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.","id":"OG000","title":"Arm A: Rituximab Retreatment"},{"description":"1000 mg rituximab initial treatment on day 1 and day 15 plus 10-25 mg/wk methotrexate followed by re-treatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/wk methotrexate.","id":"OG001","title":"Arm B: Placebo Retreatment"}],"paramType":"MEAN","populationDescription":"Participants from the Intent-to-treat population, that includes all participants randomized to Retreatment with data available for analyses.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 48","title":"Change From Baseline in American College of Rheumatology (ACR) Core Set Component: Subject's Assessment of Pain at Week 48","type":"SECONDARY","unitOfMeasure":"millimeter (mm)"}